Published in Expert Rev Anticancer Ther on July 01, 2006
Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg (2012) 1.72
Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. Acad Radiol (2009) 1.67
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells (2013) 1.49
CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One (2011) 1.44
Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res (2007) 1.17
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res (2011) 1.15
Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res (2009) 1.12
Preventing growth of brain tumors by creating a zone of resistance. Mol Ther (2008) 1.10
Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med (2011) 1.05
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res (2012) 1.05
Novel delivery strategies for glioblastoma. Cancer J (2012) 1.01
Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol (2009) 0.99
Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adh Migr (2009) 0.98
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother (2009) 0.95
Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience. Neurosurg Rev (2009) 0.94
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol (2013) 0.93
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev (2011) 0.91
Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther (2009) 0.89
Pediatric glioblastoma multiforme: A single-institution experience. Indian J Med Paediatr Oncol (2012) 0.89
Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway. J Exp Clin Cancer Res (2014) 0.86
Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. J Neurol (2008) 0.84
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS One (2013) 0.84
Proteomic analysis of glioma chemoresistance. Curr Neuropharmacol (2012) 0.79
A Long Noncoding RNA ZEB1-AS1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma. Int J Mol Sci (2016) 0.79
Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma. PLoS One (2016) 0.79
Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther (2008) 0.78
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas. Anticancer Drugs (2015) 0.78
Over-expression of the long non-coding RNA HOTTIP inhibits glioma cell growth by BRE. J Exp Clin Cancer Res (2016) 0.77
Transcriptional upregulation of microtubule-associated protein 2 is involved in the protein kinase A-induced decrease in the invasiveness of glioma cells. Neuro Oncol (2015) 0.77
Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther Deliv (2015) 0.77
High expression of long noncoding RNA HULC is a poor predictor of prognosis and regulates cell proliferation in glioma. Onco Targets Ther (2016) 0.76
RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. Oncol Lett (2016) 0.76
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. Sci Rep (2016) 0.75
Bidirectional function of shenghe powder on repair of radiation-induced DNA damage in glioma and astrocyte. Afr J Tradit Complement Altern Med (2010) 0.75
Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. Int J Clin Exp Pathol (2015) 0.75
Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect? Rare Tumors (2017) 0.75
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 3.63
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (2009) 1.97
Molecularly targeted therapy for malignant glioma. Cancer (2007) 1.96
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Biology of glioma cancer stem cells. Mol Cells (2009) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
Informed consent in pediatric surgery: Do parents understand the risks? Arch Otolaryngol Head Neck Surg (2010) 1.55
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol (2011) 1.49
Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell (2011) 1.49
Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun (2011) 1.39
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res (2008) 1.35
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 1.35
Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem (2009) 1.33
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res (2004) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol (2010) 1.32
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29
Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci (2008) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol (2010) 1.26
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer (2005) 1.21
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res (2009) 1.18
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J (2011) 1.10
Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res (2005) 1.10
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol (2007) 1.10
Diagnosis and treatment of high-grade astrocytoma. Neurol Clin (2007) 1.08
β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res (2013) 1.08
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer (2005) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer (2013) 1.06
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (2014) 1.05
EGFR mutations and sensitivity to gefitinib. N Engl J Med (2004) 1.05
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem (2004) 1.04
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer (2010) 1.03
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol (2011) 1.02
The evolving landscape of glioblastoma stem cells. Curr Opin Neurol (2013) 1.02
The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol (2008) 1.01
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci (2012) 0.99
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res (2013) 0.99
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther (2007) 0.98
New approaches to primary brain tumor treatment. Anticancer Drugs (2006) 0.96
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) (2006) 0.96
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol (2008) 0.96
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res (2006) 0.95
Notch signaling in cancer stem cells. Adv Exp Med Biol (2012) 0.95
NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem (2009) 0.95
Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci (2009) 0.95
Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci (2005) 0.95
Twisted tango: brain tumor neurovascular interactions. Nat Neurosci (2011) 0.95
Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol (2010) 0.94
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest (2014) 0.93
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev (2011) 0.92
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol (2010) 0.91
Cancer stem cell-specific scavenger receptor 36 drives glioblastoma progression. Stem Cells (2014) 0.89
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol (2012) 0.89
Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma. Cancer Res (2012) 0.88
Glioma development: where did it all go wrong? Cell (2011) 0.88
Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des (2007) 0.88
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol (2009) 0.87